Lipid Management for Secondary Prevention in Atherosclerotic Cardiovascular Disease: A Scoping Review and Scientific Report
Atherosclerotic cardiovascular disease (ASCVD) is associated with a very high risk of secondary cardiovascular events. Elevated low-density lipoprotein cholesterol (LDL-C) is a major determinant in the progression of ASCVD and in the onset of associated adverse events. Consequently, rigorous control of LDL-C is a cornerstone of secondary prevention strategies, typically achieved through statin therapy, either as monotherapy or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors. Recent large-scale clinical trials have demonstrated that intensive LDL-C lowering significantly reduces cardiovascular risk, leading to updated guidelines in the United States and Europe that advocate for more aggressive LDL-C treatment targets for secondary prevention in ASCVD. In this context, a working group established in the Japan Atherosclerosis Society performed a scoping review of LDL-C treatment targets for the secondary prevention of ASCVD. The working group systematically reviewed the available evidence for coronary artery disease (including acute and chronic coronary syndrome), atherothrombotic brain infarction, and peripheral artery disease, all of which are defined as ASCVD. The aim was to assess the evidence-based LDL-C treatment targets for the secondary prevention of defined ASCVD in Japanese patients.
Authors
- Takenobu Kunieda (ORCID: https://orcid.org/0000-0002-3672-4305)
- Nobuhiro Ayuzawa (ORCID: https://orcid.org/0000-0002-2703-867X)
- Hiroaki Okazaki (ORCID: https://orcid.org/0000-0002-9490-4929)
- Shigeru Shibata (ORCID: https://orcid.org/0000-0002-6868-0626)
- Kazuma Oyama (ORCID: https://orcid.org/0000-0002-4001-7312)
- Mitsuhiro Nishimoto (ORCID: https://orcid.org/0000-0001-9542-847X)
- Masayuki Yoshida (ORCID: https://orcid.org/0000-0002-7198-8357)
- Masahiro Natsuaki (ORCID: https://orcid.org/0000-0002-0189-2317)
- Shingo Matsumoto (ORCID: https://orcid.org/0000-0003-3774-5973)
- Yusuke Yakushiji
- Shun Kohsaka
- Hidehiro Kaneko
- Atsushi Mizuno
- Yuichi Saito
- Akihiro Nomura
- Mariko Harada-Shiba
- Kyoichiro Tsuchiya
- Koichi Node
- Atsushi Tanaka
- Michio Shimabukuro
- Hiroshi Yamagami
- Hitoshi Shimano
Institutions
- Kanazawa University (JP)
- Kansai Medical University (JP)
- Toho University (JP)
- Fukushima Medical University (JP)
- University of Tsukuba (JP)
- Jichi Medical University (JP)
- Chiba University (JP)
- Saga University (JP)
- Kyorin University (JP)
- Tohoku University (JP)
- Keio University (JP)
- Life Science Institute (JP)
- University of Yamanashi Hospital (JP)
- KES International (GB)
- Jichi Medical University Hospital (JP)
- Mita Hospital (JP)
- The University of Tokyo (JP)
- Teikyo University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Journal of Atherosclerosis and Thrombosis
- Published
- 2025-12-21
- DOI
- https://doi.org/10.5551/jat.65908
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Medpace
- Boston Scientific Corporation
- Stryker
- Abbott Japan
- Kowa Company
- Boston Scientific Japan
- Boehringer Ingelheim Japan
- Novo Nordisk
- Astellas Pharma
- Otsuka Pharmaceutical
- Astellas Foundation for Research on Metabolic Disorders
- Mitsubishi Tanabe Pharma Corporation
- Novartis Pharma
- Eli Lilly Japan
- Bayer Yakuhin
- Medtronic Japan
- Daiichi Sankyo Europe